Commetric

🎉 Exciting News Alert! 🎉

We're proud to share that Commetric has been shortlisted in two categories at the prestigious DataComms Awards 2023! 🏆

✅️ Firstly, our collaborative work with EY on understanding brand positioning in a post-COVID digital transformation sector has been recognised.
✅️ Our second nomination with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) underlines our joint efforts in effectively communicating a groundbreaking scientific breakthrough amidst the global pandemic.

🔗 https://shorturl.at/sBXY1

Commetric Shortlisted for 2 DataComms Awards - Commetric We are thrilled to announce that Commetric has been officially shortlisted in the DataComms Awards 2023, a prestigious event celebrating the integral role data has come to play in modern communications strategies. The awards recognise the transformative power of data across a variety of sectors, hig...

🦠 Our latest article discusses how top brands are promoting dietary supplements in the COVID aftermath, helping you stay fit and healthy! 💪

🔬 Dive into the science-backed benefits and discover how premium supplements can support your immune system, enhance energy levels, and promote overall wellness. 💊

🔗 Read the full analysis here: https://shorturl.at/fprDK

💬 Share your thoughts in the comments and tag a friend who needs a health boost! 🤝

Survival of the Fittest: How Brands Promote Dietary Supplements in the Covid Aftermath - Commetric Our media analysis found that the debate around dietary supplements continues to centre on their efficacy, with companies such as Nestlé, Unilever, GNC, and Herbalife adopting proactive PR strategies to address this challenge and communicate the scientific basis of their products. We also found tha...

📣 The 2023 ASCO Annual Meeting presented a multitude of clinical research data on cancer care practices, with a major focus on advancements in breast cancer treatment. 💉

📊 Our media analysis found that Novartis’ Kisqali was widely praised for its promise of boosting survival and significantly reducing the chance of recurrence, while Merck’s Keytruda was framed as a new standard of care.

💊 Additionally, there was a renewed focus on antibody-drug conjugate pipelines and a shift towards patient-centred care in oncology, emphasising the importance of integrating patients into treatment decision-making.

🔗 Dive into the full media analysis to discover more about the impactful insights: https://shorturl.at/nGIMV

ASCO 2023 Unleashed New Era of Patient Power and Cutting-Edge Therapies. Here Are the PR Takeaways - Commetric The 2023 ASCO Annual Meeting presented a multitude of clinical research data on cancer care practices, with a major focus on advancements in breast cancer treatment. Our media analysis found that Novartis’ Kisqali was widely praised for its promise of boosting survival and significantly reducing t...